Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, responsible for millions of fatalities each year. Early detection and timely intervention can prevent up to 80% of these deaths, but a major challenge lies in identifying at-risk individuals before critical events like strokes or heart attacks occur. Many patients only seek medical care after severe symptoms arise, often too late for effective treatment.
AIATELLA’s mission is to change that by leveraging advanced artificial intelligence to streamline and improve cardiovascular imaging analysis. The company’s vision is to help prevent 100 million strokes globally by making early, accurate detection accessible and routine.
Strategic investment to fuel growth
The Finnish medtech startup AIATELLA has secured a €2 million funding round. This round was led by Nordic Science Investments, with Specialist VC, Harjavalta Ventures, Business Finland, and a syndicate of angel investors also participating. The round led by Nordic Science Investments reflects strong confidence in AIATELLA’s technology and market potential. Nordic Science Investments specialises in supporting university spin-offs that transform scientific breakthroughs into commercially viable innovations, making it a natural partner for AIATELLA.
Other backers, including Harjavalta Ventures, Business Finland, and angel investors, bring expertise and resources to help the company navigate clinical approval processes in multiple countries, including the UK, France, and the United States.
AIATELLA has also received a grant from the Instrumentariumin Tiedesäätiö sr, a private, non-profit organisation supporting medical, technical, and scientific research. This further validates the importance of AIATELLA’s preventative approach to cardiovascular disease.
These funds will enable AIATELLA to complete critical clinical trials needed for regulatory certification, refine its AI models, and scale manufacturing of its portable screening devices. The company’s clear path to impact, combining speed, accuracy, and accessibility, positions it well to become a global leader in cardiovascular diagnostics.
How was the idea born?
Founded in Helsinki in 2022 by Jack Parker and Onni Eriksson, AIATELLA combines deep clinical insight with state-of-the-art AI to tackle a traditionally slow and manual process. Onni Eriksson is a Finnish entrepreneur with a technical background. Before co-founding AIATELLA, he led a 3D design company, gaining valuable experience in software development and innovation.
Jack Parker is a biomedical scientist with a clinical research and cardiology background. His studies in the UK led him to work within the NHS, where he observed firsthand the challenges faced by radiologists dealing with increasing volumes of medical images. This experience highlighted the need for more efficient diagnostic tools. Motivated by a personal connection, his father had recently suffered a heart attack, Parker co-founded AIATELLA to address these issues. He focuses on the company’s clinical aspects, regulatory processes, and strategic direction.
Parker and Eriksson met at a hackathon in Helsinki and quickly realised that their combined expertise could transform healthcare. Their first investor was Parker’s mentor, an American doctor, who believed in their vision from the start.
Faster and smarter cardiovascular diagnosis
The company’s flagship technology, Automated Image Measurement (AIM), uses images from common imaging modalities, such as MRI, CT, and ultrasound, to detect and quantify vascular abnormalities with unprecedented speed and accuracy. Specialists might spend up to an hour manually measuring and documenting changes in vascular structures. Still, AIATELLA’s AIM technology completes the task in minutes, enabling clinicians to dedicate more time to patient care rather than administrative burdens.
AIATELLA’s technology has already been applied to identify multiple potentially life-threatening cardiovascular disease cases, which otherwise may not have been found until it was too late.
Clinical validation has shown that AIM can deliver measurements in seconds with accuracy comparable to expert cardiologists. The company has filed for a patent (Finland Patent Application 20235369) for its machine learning-based landmark and segment detection method.
How AIATELLA addresses health inequities through data and access
A key priority for AIATELLA is tackling disparities in cardiovascular health outcomes linked to gender and ethnicity. Symptoms and disease progression often differ across demographic groups, but existing screening programs frequently overlook these variations. AIATELLA aims to generate valuable insights into how cardiovascular diseases manifest differently among various ethnicities and sexes by enabling large-scale, diverse population screening.
AIATELLA is committed to ensuring representation of women and minority populations in its research and product development. It runs clinical studies focused on understanding barriers to care and how diseases present and progress differently by sex and demographics. This commitment extends to its AI development, where inclusive algorithms are created to account for diverse populations.
This data-driven approach will help tailor diagnostic criteria and treatment strategies to serve underrepresented groups better, working to close the health gap and ensure equitable care for all patients.
What’s so special about AIATELLA? AI meets medical imaging
The AIM system focuses on the aorta, the body’s largest artery, and a critical site for cardiovascular complications. By automating the measurement and monitoring of aortic changes over time, the technology provides clinicians with reliable, consistent data that can signal disease progression early on.
AIATELLA envisions expanding its technology beyond the aorta to cover every major blood vessel, offering a comprehensive vascular health assessment. This broad coverage will further enhance clinicians’ ability to diagnose, monitor, and manage cardiovascular disease with precision and personalisation.
From clinical tools to portable screening technology
Beyond tools for medical professionals, AIATELLA is pioneering a portable ultrasound-based screening solution designed for mass preventative use. This innovative device allows rapid detection and quantification of carotid artery narrowing, a significant predictor of stroke risk, in just minutes, anywhere and anytime.
The portable screening technology has already been used in partnership with medical professionals at screening events in Finland and the UK, helping identify tens of potentially at-risk individuals who were then referred to healthcare professionals for further evaluation.
This screening technology’s portability and ease of use open doors for widespread cardiovascular risk assessment outside traditional healthcare settings. It can be integrated into occupational health checks, insurance evaluations, and public health initiatives such as mobile blood donation drives or vaccination programs, effectively removing barriers that often delay early diagnosis.
Already deployed in screening events across Finland and the UK in collaboration with medical professionals, AIATELLA’s portable technology has identified dozens of potentially dangerous arterial narrowing individuals who were subsequently referred for specialist evaluation and treatment.
Behind AIATELLA: Revolutionising radiology for preventative medicine
AIATELLA’s technology marks a transformative step in radiology, replacing slow, labour-intensive manual processes with fast, automated analysis powered by AI. By making image analysis up to 100 times faster, the technology enhances diagnostic accuracy and consistency while freeing clinicians to focus on personalised patient care.
The company’s solutions are hosted securely on the Microsoft Azure Cloud and showcased at major industry events such as SLUSH and ChangeNOW 2025, where live demonstrations highlighted their real-world impact.
This efficiency gain is essential for shifting from reactive treatment to proactive prevention in cardiovascular health, which could save millions of lives and reduce healthcare costs worldwide.
Looking ahead: A future of comprehensive vascular health
With clinical certification and broader adoption on the horizon, AIATELLA aims to expand the reach of its AI tools to cover the full vascular system and integrate its portable screening technology into routine healthcare worldwide. The company envisions a future where early cardiovascular risk detection is as commonplace as routine blood pressure checks, accessible to all regardless of location or socioeconomic status.
Pilots are currently underway with multiple hospitals in the UK and USA, as well as with Finnish healthcare provider Pihlajalinna. The company is running clinical studies focused on understanding barriers to care and investigating how diseases present and progress differently by sex and demographic.
With recent funding enabling clinical certification and the launch of a portable screening tool, the company is well-positioned to help doctors detect life-threatening vascular diseases earlier and more efficiently, ultimately saving lives through better prevention and personalised medicine.
“When I was in medical education in the UK, my mentor told me that you can save thousands of lives in the operating room, but if you want to save millions, that happens in society. I saw that the current imaging workflows take a lot of time and resources, with ever-increasing scan volumes and a global shortage of radiologists leading to large backlogs; Radiologists were, and are, burning out. Our technology helps medical professionals analyse imaging much more efficiently, and at an earlier stage, so patients can get help before it’s too late,” stated Jack Parker, Co-Founder and CEO at AIATELLA.
“AIATELLA’s solutions have the potential to streamline our workflow by automating measurements in cardiovascular imaging, saving clinicians significant time per scan, and allowing us to focus our attention on interpretation. The scalability of this technology means we can provide standardised expert-level measurements regardless of the degree of expertise of the reporter. I am excited about the impact this could have for the NHS regarding workflow optimisation and equitable patient care,” said Anna Beattie, Consultant Cardiothoracic Radiologist, Radiology Research and AI Lead at Newcastle Hospitals NHS Foundation Trust.
“AIATELLA is tackling one of the most significant opportunities in medicine: using AI to transform radiology. The company is perfectly positioned to lead the shift from reactive to preventative cardiovascular care and to replace outdated, manual workflows with intelligent, automated diagnostics,” said Alexandra Gylfe, Partner at Nordic Science Investments.
With this new funding and international recognition, AIATELLA is poised to become a global leader in cardiovascular diagnostics, transforming the standard of care and potentially saving millions of lives through earlier, more equitable, and more accurate detection.
